Holen Sie sich die Stockscreener-App
17.48
4.32%
-0.79
Schlusskurs vom Vortag:
$18.27
Offen:
$18.36
24-Stunden-Volumen:
775.98K
Relative Volume:
0.59
Marktkapitalisierung:
$1.45B
Einnahmen:
$46.02M
Nettoeinkommen (Verlust:
$-70.80M
KGV:
-9.6044
EPS:
-1.82
Netto-Cashflow:
$-1.61M
1W Leistung:
-4.43%
1M Leistung:
+27.68%
6M Leistung:
+80.95%
1J Leistung:
+117.68%
1-Tages-Spanne:
$16.88
$18.50
1-Wochen-Bereich:
$16.88
$18.50
52-Wochen-Spanne:
$3.91
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
Firmenname
Eyepoint Inc
Sektor
Branche
Telefon
617-926-5000
Adresse
480 PLEASANT STREET, WATERTOWN, MA
Vergleichen Sie EYPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
17.48 | 1.51B | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-07 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-22 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-02 | Eingeleitet | Mizuho | Buy |
| 2023-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-07-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2021-01-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-04-06 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | Fortgesetzt | Laidlaw | Buy |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Eyepoint Inc Aktie (EYPT) Neueste Nachrichten
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 6.1%Here's What Happened - MarketBeat
The Year-End 2025 Biotech Rally And What It Means For 2026 - Benzinga
Understanding the Setup: (EYPT) and Scalable Risk - Stock Traders Daily
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Analysts - MarketBeat
EyePoint, Inc.Common Stock (Nasdaq:EYPT) Stock Quote - FinancialContent
127,489 Shares in Eyepoint Pharmaceuticals, Inc. $EYPT Purchased by Corient Private Wealth LLC - MarketBeat
Why EyePoint (EYPT) Is Up 9.6% After Upbeat Earnings Revisions And Momentum SignalsAnd What's Next - Sahm
EyePoint (EYPT): Assessing Valuation After Earnings Upgrades and Strong Momentum-Driven Share Gains - Yahoo Finance
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 6.2%Time to Sell? - MarketBeat
EyePoint Earnings Notes - Trefis
EyePoint (EYPT) Is Up 9.01% in One Week: What You Should Know - Yahoo Finance
3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 - Zacks Investment Research
Will EyePoint Pharmaceuticals Inc. stock rally after Fed decisionsWeekly Risk Summary & Technical Analysis for Trade Confirmation - Улправда
EyePoint (EYPT) Price Target Increased by 10.87% to 36.80 - Nasdaq
Is EyePoint Pharmaceuticals Inc. stock dividend yield sustainable2025 Technical Overview & Expert Approved Momentum Ideas - Улправда
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Rating Increased to Strong-Buy at TD Cowen - MarketBeat
Why (EYPT) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Can EyePoint Pharmaceuticals Inc. stock resist market sell offsMarket Risk Summary & High Conviction Buy Zone Picks - Улправда
Will EyePoint Pharmaceuticals Inc. stock continue dividend increases2025 Short Interest & Step-by-Step Swing Trade Plans - Улправда
Is EyePoint Pharmaceuticals Inc a good long term investmentOptions Trading Strategies & Free Tap Rapid Wealth - earlytimes.in
How sustainable is EyePoint Pharmaceuticals Inc. stock dividend payoutMarket Sentiment Review & Precise Trade Entry Recommendations - DonanımHaber
Is EyePoint Pharmaceuticals Inc. stock overvalued by current metricsPortfolio Value Report & Weekly High Conviction Trade Ideas - Улправда
Will EyePoint Pharmaceuticals Inc. stock reach all time highs in 2025 - DonanımHaber
Inflation Data: How EyePoint Pharmaceuticals Inc. (PV3B) stock compares with market leadersJuly 2025 Sentiment & Community Trade Idea Sharing Platform - Улправда
How EyePoint Pharmaceuticals Inc. stock reacts to oil pricesWeekly Stock Recap & Expert Approved Trade Ideas - DonanımHaber
Can EyePoint Pharmaceuticals Inc. stock maintain growth trajectory2025 Growth vs Value & Consistent Profit Trade Alerts - Улправда
Should I hold or sell EyePoint Pharmaceuticals Inc. stock in 2025July 2025 Rallies & Low Risk Growth Stock Ideas - Улправда
Support Test: Will EyePoint Pharmaceuticals Inc. stock see PE expansionDividend Hike & Low Risk Entry Point Guides - Улправда
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Globe and Mail
EyePoint, Inc. CEO Jay S. Duker to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
Eye disease drug developer to present at major healthcare conf - Stock Titan
EyePoint (STU:PV3B) OCF Margin % : -6,144.59% (As of Sep. 2025) - GuruFocus
EyePoint reports inducement grants under NASDAQ listing rule - MSN
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading 5.8% HigherWhat's Next? - MarketBeat
EyePoint (EYPT) Grants Stock Options to New Employees as Inducem - GuruFocus
Eyepoint reports inducement grants under Nasdaq listing rule - marketscreener.com
Eyepoint Reports Inducement Grants Under NASDAQ Listing Rule - TradingView — Track All Markets
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Buy Recommendation for EyePoint Pharmaceuticals: Strong Clinical Positioning and Market Potential of Duravyu in Wet AMD - TipRanks
Certain Pre-Funded Warrants of EyePoint, Inc. are subject to a Lock-Up Agreement Ending on 14-DEC-2025. - marketscreener.com
Certain Stock Options of EyePoint, Inc. are subject to a Lock-Up Agreement Ending on 14-DEC-2025. - marketscreener.com
68,889,649 Common Stock of EyePoint, Inc. are subject to a Lock-Up Agreement Ending on 14-DEC-2025. - marketscreener.com
Cormorant Asset Management Reduces Stake in EyePoint Pharmaceuti - GuruFocus
After Leaping 38% EyePoint, Inc. (NASDAQ:EYPT) Shares Are Not Flying Under The Radar - simplywall.st
EyePoint, Inc.: Dividend historical data and projections - marketscreener.com
Update Report: Is EyePoint Pharmaceuticals Inc stock positioned for long term growth2025 Biggest Moves & High Accuracy Swing Trade Signals - moha.gov.vn
Stempoint Capital LP Acquires New Position in Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
EyePoint stock maintains Outperform rating at Mizuho amid competitor moves By Investing.com - Investing.com Australia
EyePoint stock maintains Outperform rating at Mizuho amid competitor moves - Investing.com India
EyePoint Pharmaceuticals (EYPT) Maintains Positive Outlook Amid Competitive Dynamics - GuruFocus
Walleye Capital LLC Has $1.88 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
Finanzdaten der Eyepoint Inc-Aktie (EYPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):